The novel LSD1 inhibitor ZY0511 suppresses diffuse large B-cell lymphoma proliferation by inducing apoptosis and autophagy

• Published in: Medical oncology (Northwood, London, England) London, England), 2021-10, Vol.38 (10), p.124-124, Article 124
• Main Authors: Liu, Huan, Wei, Jing, Sang, Na, Zhong, Xi, Zhou, Xia, Yang, Xinyu, Zhang, Jing, Zuo, Zeping, Zhou, Yang, Yang, Shengyong, Du, Junrong, Zhao, Yinglan
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - pharmacology; Apoptosis; Apoptosis - drug effects; Autophagy; Autophagy - drug effects; Cell cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation - drug effects; Hematology; Histone Demethylases - antagonists & inhibitors; Humans; Hydrazines - pharmacology; Internal Medicine; Lymphoma; Lymphoma, Large B-Cell, Diffuse - drug therapy; Medicine; Medicine & Public Health; Mice; Mice, Inbred NOD; Mice, SCID; Morpholines - pharmacology; Oncology; Original Paper; Pathology; Sulfones - pharmacology; Xenograft Model Antitumor Assays
• ISSN: 1357-0560; 1559-131X
• DOI: 10.1007/s12032-021-01572-0

Lysine-specific demethylase 1 (LSD1, also known as KDM1A) is an attractive agent for treatment of cancer. However, the anti-tumor effect of LSD1 inhibitors against diffuse large B-cell lymphoma (DLBCL) and the underlying mechanism are still unclear. Here, we report that KDM1A is overexpressed in human DLBCL tissues and negatively related to overall survival rate of DLBCL patients. ZY0511, a novel and potent LSD1 inhibitor developed by our group, inhibited the proliferation of human DLBCL cells. ZY0511 interacted with LSD1, induced methylation level of histone 3 lysine 4 and histone 3 lysine 9 in DLBCL cells. Mechanistically, transcriptome sequencing results indicated that ZY0511 induced the genes enrichment significantly related to cell cycle, autophagy, and apoptosis signaling pathways. Further study confirmed that ZY0511 blocked cell cycle at G0/G1 phase and expression of CDK4 and cyclin D1. ZY0511 decreased mitochondrial membrane potential and induced apoptosis, which can be reverted by a pan-caspase inhibitor, Z-VAD-FMK. Moreover, ZY0511 treatment significantly increased autophagy-associated marker proteins and autophagosomes formation in DLBCL cells. In vivo xenograft experiments confirmed that intraperitoneal administration of ZY0511 significantly suppressed SU-DHL-6 xenograft tumor growth in vivo. In conclusion, our findings identify that ZY0511 inhibits DLBCL growth both in vitro and in vivo via the induction of apoptosis and autophagy, and LSD1 inhibitor might be a promising strategy for treating DLBCL.